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Patients with chronic kidney disease have elevated
circulating asymmetric dimethylarginine (ADMA). Recent
studies have suggested that ADMA impairs endothelial nitric
oxide synthase (eNOS) by effects other than competition with
the substrate L-arginine. Here, we sought to identify the
molecular mechanism by which increased ADMA causes
endothelial dysfunction in a chronic kidney disease model.
In wild-type mice with remnant kidney disease, blood urea
nitrogen, serum creatinine, and ADMA were increased
by 2.5-, 2-, and 1.2-fold, respectively, without any change
in blood pressure. Nephrectomy reduced endothelium-
dependent relaxation and eNOS phosphorylation at Ser1177
in isolated aortic rings. In transgenic mice overexpressing
dimethylarginine dimethylaminohydrolase-1, the enzyme
that metabolizes ADMA, circulating ADMA was not increased
by nephrectomy and was decreased to half that of wild-type
mice. These mice did not exhibit the nephrectomy-induced
inhibition of both endothelium-dependent relaxation and
eNOS phosphorylation. In cultured human endothelial cells,
agonist-induced eNOS phosphorylation and nitric oxide
production were decreased by ADMA at concentrations
less than that of L-arginine in the media. Thus, elevated
circulating ADMA may be a cause, not an epiphenomenon, of
endothelial dysfunction in chronic kidney disease. This effect
may be attributable to inhibition of eNOS phosphorylation.
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The prevalence of chronic kidney disease (CKD) is increasing
worldwide.1,2 Approximately 50% of the end-stage renal
disease patients die from cardiovascular causes3–5 and their
cardiovascular mortality is 500-fold greater compared with
that of age-matched controls with normal renal function.5
The Framingham Heart Study revealed that mild renal failure
was associated with increased prevalence of death and
cardiovascular events even in the general population.6
Endothelial dysfunction was documented from the early
stage of renal failure,7 suggesting that endothelial dysfunction
is one of the initial mechanisms that lead to cardiovascular
complications in CKD patients.
Asymmetric dimethylarginine (ADMA) is generated dur-
ing the process of protein turnover and is actively degraded
by the intracellular enzyme, dimethylarginine dimethylami-
nohydrolase (DDAH).8–13 ADMA is an endogenous inhibitor
of all types of nitric oxide synthases (NOSs).14,15 It has long
been thought that the NOS inhibition by ADMA is
attributable to its competitive inhibition as an L-arginine
analog.10,16 However, there is increasing evidence that ADMA
may have additional effects that are independent of the
competitive inhibition of NOS although the precise mechan-
isms are unknown.17–19
We have shown that circulating ADMA levels are corre-
lated with the thickness of the carotid artery in a general
healthy population.20 Thereafter, ADMA has been increas-
ingly recognized as a putative biomarker in cardiovascular
diseases.21 It was reported that circulating ADMA levels were
elevated in CKD patients.16,22,23 Reduced bioavailability of
nitric oxide (NO) has been documented in CKD patients,
concurrently with endothelial dysfunction.24–26 However, it
remains undetermined whether the elevation of circulating
ADMA level is a cause or an epiphenomenon of endothelial
damages in patients or animal models of CKD.
The aims of this study were to examine whether increased
circulating ADMA causes endothelial dysfunction in a
mouse model of CKD and, if so, to investigate the molecular
mechanism. To address the contribution of circulating
ADMA to endothelial dysfunction in CKD, we created 5/6
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nephrectomized (Nx) models in DDAH-1 overexpressed
mice having reduced circulating ADMA levels. The effects of
ADMA on endothelial NOS (eNOS) activity were investi-
gated in cultured human umbilical vein endothelial cells
(HUVECs).
RESULTS
5/6 Nx causes renal failure without hypertension
Nx increased blood urea nitrogen (BUN) and serum
creatinine levels in wild-type (WT) mice. The elevations of
BUN and serum creatinine in human DDAH-1–transgenic
(TG) mice receiving Nx (TGþCKD) were similar to those in
WT mice receiving Nx (WTþCKD) 4 weeks after the
operation (Figure 1a and b). There were no differences in
systolic blood pressure and heart rate among the four groups
(Figure 1c and d). We did not observe apparent morphological
and histological changes in the heart and aorta in WTþCKD,
TGþ sham, and TGþCKD mice (data not shown).
Serum ADMA levels
In WTþCKD mice, serum ADMA levels were increased by
20% compared with those in WTþsham mice (Figure 1e).
TGþ sham mice showed a 50% reduction in serum ADMA
levels compared with WTþsham mice. In TG mice, Nx did
not increase the ADMA levels.
Endothelium-dependent relaxation of aortic rings
In WTþsham mice, acetylcholine (Ach) induced a dose-
dependent relaxation of the aortic rings precontracted with
phenylephrine (Figure 2 and Supplementary Table S1 online).
The endothelium-dependent relaxation was significantly
impaired in isolated aortic rings obtained from WTþCKD
mice. In TGþ sham mice, the endothelium-dependent
relaxation was similar to that in WTþsham mice. The Nx-
induced endothelial dysfunction was prevented in TG mice.
These results were confirmed by the area under the curve
analysis (Table 1). The half-maximal inhibitory concentration
(IC50) of Ach was significantly greater in WTþCKD mice
compared with WTþsham mice, suggesting that ADMA
reduced the sensitivity for Ach after Nx in WT mice.
However, the IC50 levels in TGþ sham and TGþCKD mice
did not differ from that in WTþsham mice (Table 1).
Vascular eNOS expression and phosphorylation in CKD mice
The Ser1177 residue of eNOS is a key phosphorylation site
that positively regulates eNOS enzyme activity independently
of intracellular calcium concentrations.27 We investigated the
eNOS expression and phosphorylation levels in the aorta of
WT and TG mice with or without Nx (Figure 3a and b). Nx
did not affect eNOS protein expression levels in WT mice.
However, eNOS phosphorylation at Ser1177 was attenuated
by Nx, suggesting the inhibition of eNOS activity in
WTþCKD mice. In TGþ sham mice, the eNOS expression
and phosphorylation levels were similar to those in
WTþsham mice. The reduction in eNOS phosphorylation
observed in WTþCKD mice was abolished in TGþCKD
mice. In addition, we examined urinary nitrate/nitrite (NOx)
excretion in 24 h as an indicator of NO production in vivo
(Figure 3c). Urinary NOx excretion was reduced by 66% in
WTþCKD mice compared with WTþsham mice. In
TGþ sham mice, urinary NOx excretion was much higher
than that in WTþsham mice. The NOx excretion was
significantly reduced in TGþCKD mice compared with
TGþ sham mice. But, the NOx levels in TGþCKD mice
were similar to the levels in WTþsham mice and
significantly higher than those in WTþCKD mice.
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Figure 1 |Nephrectomy (Nx) causes moderate renal failure and increases circulating asymmetric dimethylarginine (ADMA). The
effects of Nx on blood urea nitrogen (BUN) (a), serum creatinine (b), systolic blood pressure (SBP) (c), heart rate (d), and serum ADMA (e) at 4
weeks after Nx or sham operation in wild-type (WT) mice and dimethylarginine dimethylaminohydrolase-1 transgenic (TG) mice. WT mice
receiving sham operation (WTþ sham), n¼ 9; WT mice receiving Nx (WTþCKD), n¼ 9; TG mice receiving sham operation (TGþ sham),
n¼ 6; TG mice receiving Nx (TGþCKD), n¼ 6. Values are mean±s.e.m. **Po0.01. b.p.m., beats per minute; CKD, chronic kidney disease;
NS, not significant.
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Effects of ADMA on endothelial-dependent relaxation
To determine whether ADMA would directly impair
endothelial function, we examined the effects of exogenous
ADMA treatment on the endothelium-dependent relaxation
of the aorta in WT mice (Figure 4). The endothelium-
dependent relaxation was dose-dependently inhibited by pre-
treatment with 1 106–1 104 mol/l ADMA, although the
inhibition was not statistically significant for 106 mol/l
ADMA (Figure 4b and Table 2). The IC50 of Ach was
significantly increased by 1 104 mol/l ADMA pre-treat-
ment compared with 0 mol/l ADMA (Table 2).
Effects of ADMA on eNOS function in HUVECs
To further determine the molecular mechanisms of the
endothelial dysfunction by ADMA, we examined the effects
of ADMA on eNOS phosphorylation using cultured
HUVECs (Figure 5a and b). In HUVECs cultured in the
media containing 5 104 mol/l L-arginine, ADMA
(1 106 and 1 104 mol/l) did not affect the baseline
eNOS phosphorylation at Ser1177. However, ADMA dose-
dependently inhibited the vascular endothelial growth factor-
induced eNOS phosphorylation. Next, we examined the
effects of ADMA on the phosphorylation of extracellular
signal-related protein kinase (ERK) and Akt, putative
upstream regulatory molecules of eNOS phosphorylation.
ADMA dose-dependently inhibited the vascular endothelial
growth factor-induced ERK1/2 phosphorylation, without
changing the baseline phosphorylation. In contrast, ADMA
did not affect Akt phosphorylation at Ser473. Moreover, we
confirmed the effects of ADMA on NO production in
HUVECs. ADMA inhibited the vascular endothelial growth
factor-stimulated NO release into the conditioned media
(Figure 5c).
DISCUSSION
The salient findings of this study are as follows: (1) Nx
induced moderate renal failure to a similar extent in WT and
DDAH-1–TG mice without elevating blood pressure; (2) Nx
impaired endothelium-dependent relaxation of isolated
aortic rings in WT mice with the elevation of circulating
ADMA levels, but not in TG mice having reduced ADMA
levels; (3) Nx attenuated eNOS phosphorylation at Ser1177,
an indicator of eNOS activity, in the aorta of WT mice, but
not in TG mice; (4) ADMA treatment suppressed the agonist-
induced eNOS phosphorylation and NO production in
HUVECs cultured under the L-arginine-rich condition.
As shown in Figure 1, a mouse with Nx had 2.5- and 2-
fold increases in BUN and creatinine, respectively, without
blood pressure elevation, suggesting that it is a CKD model
representing moderate renal failure without hypertension.
This study was performed in young mice, and the observa-
tion period was rather short because we focused on
investigating the relationship between elevated circulating
ADMA and endothelial function in the CKD model before
cardiovascular damages and remodeling had developed. TG
mice showed a 50% reduction in baseline ADMA levels
(Figure 1e). This finding is consistent with that of previous
reports.28,29 Although circulating ADMA levels were sig-
nificantly increased by Nx in WT mice, Nx did not change the
ADMA levels in TG mice, probably due to augmented ADMA
degradation by overexpressed DDAH-1. Thus, TGþCKD
mice were used as a model animal having renal failure
without elevated circulating ADMA levels. It is noteworthy
that the Nx-induced impairment of endothelium-dependent
relaxation was prevented in TGþCKD mice (Figure 2 and
Supplementary Table S1 online). As the blood pressure level
and the extent of renal failure were similar in WTþCKD and
TGþCKD mice (Figure 1), it is suggested that the elevation
of circulating ADMA levels has a causal relation to the
Nx-induced endothelial dysfunction in WT mice (Figures 2
and 4). To the best of our knowledge, this is the first
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Figure 2 | Endothelium-mediated relaxation is impaired in the
aorta of wild-type (WT)þCKD mice, but not in transgenic
(TG)þCKD mice. (a) Representative traces showing the acetyl-
choline (Ach)-induced relaxation in phenylephrine (PE)-pre-treated
rings of the descending aorta obtained from WTþ sham (left) and
WTþCKD (right) mice. (b) Pooled data of the Ach-induced
relaxation in WTþ sham (n¼ 7), WTþCKD (n¼ 4), TGþ sham
(n¼ 5), and TGþCKD (n¼ 4). Values are mean±s.e.m. **Po0.01
vs. WTþ sham mice as a result of two-way analysis of variance.
yPo0.05 vs. WTþ sham mice as a result of Tukey–Kramer’s
post-hoc analysis. CKD, chronic kidney disease.
Table 1 | Effects of CKD on IC50 and AUC of acetylcholine-
induced relaxation of the aortic rings of WT and TG mice
Acetylcholine
Group n Log IC50 (mol/l) AUC (arbitrary unit)
WT+sham 9 6.67±0.62 139±21
WT+CKD 4 5.72±0.78* 49±13*
TG+sham 5 5.85±0.65 121±16
TG+CKD 4 6.44±0.67 146±36
Abbreviations: AUC, area under the curve; CKD, chronic kidney disease 5/6
nephrectomized mouse; IC50, half-maximal (50%) inhibitory concentration; Sham,
sham-operated control mouse; TG, dimethylarginine dimethylaminohydrolase-1
transgenic mouse; WT, wild-type mouse.
*Po0.05 vs. WTþ sham.
Data are expressed as mean±s.e.m.
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demonstration that elevated circulating ADMA may be a
cause, but not an epiphenomenon, of endothelial dysfunction
in CKD.
Another important novel finding of this study is that
reduction of eNOS phosphorylation at Ser1177 was asso-
ciated with endothelial dysfunction in the aorta of
WTþCKD mice, but not in TGþCKD mice (Figure 3).
Phosphorylation levels at Ser1177 determine eNOS enzyme
activity.27 Indeed, the urine NOx excretion, an indicator of
NO production in vivo, was significantly higher in TGþCKD
mice than in WTþCKD mice, suggesting eNOS phosphor-
ylation levels in the aorta are functionally associated with NO
production in the mice. Thus, it is suggested that the reduced
eNOS phosphorylation may be involved in the mechanism
accounting for the endothelial dysfunction in WTþCKD
model. The precise mechanism linking ADMA to inhibition
of eNOS phosphorylation remains unknown in this CKD
model. However, the experiments using HUVECs provided
an insight into the possible mechanism (Figure 5). It is
interesting to note that ADMA prevented the agonist-
induced eNOS phosphorylation and NO production in
HUVECs. Moreover, the phosphorylation of ERK, one of
the putative major kinases for eNOS phosphorylation, was
also inhibited by ADMA. Thus, it is possible that the
inhibition of ERK–eNOS pathway would be a mechanism
whereby ADMA impairs eNOS function. We used the culture
media containing L-arginine, the eNOS substrate, at
5 104 mol/l, which was a much higher concentration of
ADMA that was applied to HUVECs (1 106 and
1 104 mol/l). In this study, it is less likely that competitive
inhibition was the reason for the observed effects of ADMA
on NO generation. Rather, the inhibition of the ERK–eNOS
phosphorylation may be a novel mechanism of eNOS
inhibition by ADMA (Figure 6). These findings may support
the notion that ADMA has additional actions other than
competitive inhibition of eNOS.17–19 It is noteworthy that the
inhibitory effect of ADMA on eNOS phosphorylation in
HUVECs was observed at 1 106 mol/l, which corresponds
to the serum levels of ADMA in CKD mice (Figure 1).
Taken together, it is possible that the inhibition of the
ERK–eNOS phosphorylation by elevated circulating ADMA
levels would impair the endothelium-dependent relaxation in
CKD mice.
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Figure 3 |Vascular endothelial nitric oxide synthase (eNOS) activity is impaired in the aorta of wild-type (WT)þCKD mice, not
transgenic (TG)þCKD mice. Representative immunoblots (a) and the pooled data (b) demonstrating the effects of nephrectomy (Nx) on
the expression levels of eNOS, phosphorylated eNOS (p-eNOS), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in the aorta of
WTþ sham (n¼ 9), WTþCKD (n¼ 9), TGþ sham (n¼ 4), and TGþCKD (n¼ 4). The results of densitometric analysis were presented as a fold
change compared with WTþ sham. **Po0.01 vs. WTþ sham, TGþ sham, and TGþCKD. (c) Urinary excretion of total nitrate and nitrite
(NOx) in WTþ sham (n¼ 10), WTþCKD (n¼ 10), TGþ sham (n¼ 6), and TGþCKD (n¼ 6). *Po0.05, **Po0.01. Values are mean±s.e.m.
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Figure 4 |Asymmetric dimethylarginine (ADMA) impairs
endothelium-mediated relaxation in the aorta. Representative
traces (a) and pooled data (b) showing the effects of
1 106–1 104mol/l exogenous ADMA on the acetylcholine
(Ach)-induced relaxation of the phenylephrine (PE)-precontracted
aortic rings obtained from wild-type (WT)þ sham mice. After
10-min pre-treatment with 0mol/l (left) or 1 104mol/l ADMA
(right), 1 105mol/l PE was applied to the strips. **Po0.01 vs.
ADMA 0mol/l as a result of two-way analysis of variance. yPo0.05,
yyPo0.01 vs. ADMA 0mol/l as a result of Tukey–Kramer’s
post-hoc analysis.
Table 2 | Effects of ADMA on IC50 and AUC of acetylcholine-
induced relaxation of the aortic rings of WT mice
Acetylcholine
Group n Log IC50 (mol/l) AUC (arbitrary unit)
ADMA 104mol/l 9 5.53±0.31** 31±9*
ADMA 105mol/l 6 6.36±0.27 73±24*
ADMA 106mol/l 6 6.26±0.25 100±32
ADMA 0mol/l 9 6.64±0.13 125±23
Abbreviations: ADMA, asymmetric dimethylarginine; AUC, area under the curve; IC50,
half-maximal (50%) inhibitory concentration; WT, wild type.
*Po0.05, **Po0.01 vs. ADMA 0mol/l.
Data are expressed as mean±s.e.m.
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This study has several limitations. First, we used a tail-cuff
sphygmomanometer to noninvasively measure blood pres-
sure without anesthesia. Thus, we do not deny the possibility
that we may have missed subtle blood pressure differences.
Second, we used a human DDAH-1 TG expression construct
using a human b-actin promoter in this study, because the
endothelium-specific TG mice were not available at present.
Thus, we verified the overexpression of DDAH-1 in the
endothelial cells as well as smooth muscle cells of the aorta in
TG mice (Supplementary Figure S1 online). Third, 106 mol/
l ADMA reduced eNOS phosphorylation in the agonist-
stimulated HUVECs (Figure 5), whereas Ach-induced
vasorelaxation of the aortic rings was not significantly
inhibited by 106 mol/l ADMA (Figure 4). It is difficult to
simply compare the results of the HUVEC experiments and
the isometric tension study because there were many
differences in the experimental conditions. Moreover, we
did not know the intracellular concentrations of ADMA when
the same dose of ADMA was applied to the HUVECs and the
aortic rings. Finally, in vivo WTþCKD mice had an
attenuated basal eNOS phosphorylation because of CKD-
induced elevation of ADMA (Figure 3a), whereas in vitro
exogenous administration of ADMA did not affect basal
eNOS phosphorylation (Figure 5a and b). There may be
several reasons for this difference. One possibility is that there
may be currently unknown stimuli that induce basal eNOS
phosphorylation in the aorta of mice. Another may be that in
the HUVEC experiments, the effects of ADMA on basal
eNOS phosphorylation were not detected simply because the
basal phosphorylation level was low and/or because the
changes by ADMA were too small to be detected.
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Figure 6 |Proposed mechanism for endothelial dysfunction in
chronic kidney disease (CKD). The increase in circulating asym-
metric dimethylarginine (ADMA) causes endothelial dysfunction
in CKD by reducing vascular endothelial nitric oxide synthase
(eNOS) phosphorylation. Inhibition of the eNOS signaling pathway
may be an additional mechanism accounting for the eNOS
inhibition by ADMA in CKD, independently of competitive
inhibition. DDAH, dimethylarginine dimethylaminohydrolase;
NO, nitric oxide.
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In conclusion, increased circulating ADMA level caused
endothelial dysfunction in CKD mice. It was suggested that
the effect might be mediated by the inhibition of eNOS
phosphorylation, a novel mechanism of eNOS inhibition by
ADMA.
MATERIALS AND METHODS
The study protocol was reviewed and approved by the Animal
Care and Treatment Committee of Kurume University. C57BL/6J
mice, WT mice, were purchased from Charles River Laboratories
(Yokohama, Japan). Human DDAH-1–TG mice in C57BL/6J
background were purchased from Jackson Laboratory (Bar Harbor,
ME) and genotyped as previously described.28–30 A human DDAH-1
TG expression construct was prepared using human DDAH-1
complementary DNA, a human b-actin promoter, and RNA
processing signals from SV40 derived from a modified human
agouti expression vector, as described.28 Mice were housed under
standard conditions of humidity, room temperature, and a 12-h
light/12-h dark cycle with plenty of chow and water. Male mice were
used for all experiments. HUVECs were purchased from Lonza
(Basel, Switzerland).
A rabbit monoclonal antibody against human eNOS, a rabbit
polyclonal antibody against human phosphorylated eNOS at
Ser1177, a rabbit monoclonal antibody against mouse Akt, a rabbit
monoclonal antibody against human phosphorylated Akt at Ser473,
a rabbit polyclonal antibody against rat ERK, and a rabbit
monoclonal antibody against human phosphorylated ERK at
Thr202/Tyr204 were purchased from Cell Signaling Technology
(Danvers, MA), and a mouse monoclonal antibody against rabbit
glyceraldehyde-3-phosphate dehydrogenase was from Millipore
(Billerica, MA).
Animal model
Experiments included the following four groups: WT mice with sham
operation (WTþsham mice, n¼ 30); WT mice receiving Nx
(WTþCKD mice, n¼ 27); TG mice with sham operation (TGþ sham
mice, n¼ 24); and TG mice receiving Nx (TGþCKD mice, n¼ 20).
CKD mice were created by performing Nx in WT and TG mice as
previously described.31 Briefly, mice were anesthetized with 1.5%
isoflurane by inhalation. 5/6 Nx was established by surgical resection
of the upper and lower thirds of the left kidney at 10–12 weeks
followed by right Nx 1 week later. Four weeks after the establish-
ment of Nx, blood pressure and heart rate were measured using a
tail-cuff sphygmomanometer (MK-2000ST; Muromachi, Tokyo,
Japan). Briefly, mice were acclimated to a holding chamber by daily
exposure for 1 week. Once acclimated, systolic blood pressure was
measured by a tail-cuff sphygmomanometer. A total of 10
consecutive readings of systolic blood pressure were recorded and
averaged. The interobserver and intraobserver variabilities were
below 5%. One day after measuring the blood pressure and heart
rate, mice were killed with an overdose of pentobarbital (100 mg/kg
intraperitoneally). Blood was collected from the right appendage,
and then perfused with ice-cold saline for 5 min. The aorta was
immediately removed and subjected to isometric tension study or
immunoblotting analysis. For urine collection, mice were housed in
metabolic cages for 24 h before killing.
Blood and urine chemistry
Serum ADMA and urine NOx (oxidized derivatives of NO) were
measured using high-performance liquid chromatography at a
commercially available laboratory (SRL, Tokyo, Japan).32,33 BUN
and serum creatinine were measured with commercially available
kits (Denka Seiken, Tokyo, Japan and Alfresa Pharma, Osaka, Japan,
respectively).
Isometric tension study
Aortic rings obtained from the descending thoracic aorta of WT
mice and TG mice were mounted on a wire myograph (ADInstru-
ments Pty, Bella Vista, Australia) for the endothelial function assay.
After 60-min equilibration in an organ bath containing Krebs’
solution aerated with 95% CO2–5% O2 (37 1C), aortic rings were
pre-constricted with 1 105 mol/l phenylephrine. Then, an incre-
mental dose of Ach (1 107–1 104 mol/l) was applied at 10-min
intervals. To determine the effect of exogenous ADMA in the
isometric tension study, Ach-induced (Sigma-Aldrich, St Louis,
MO) relaxation was assessed in the presence of ADMA (Sigma-
Aldrich) in WT mice (n¼ 18). According to a previous study,34
1 106–1 104 mol/l ADMA was applied to the aortic rings.
Two-way analysis of variance followed by post-hoc analysis and
the area under the curve analysis was performed to compare the
differences among four groups. IC50 of Ach was calculated for
evaluating the sensitivity to Ach.
Immunoblotting
The aorta was immediately removed and snap-frozen in liquid N2.
Frozen samples were homogenized in lysis buffer containing protease
inhibitor cocktail by using FastPrep homogenizer (Thermo Savant,
Holbrook, NY) and stored at 80 1C until use. The aliquot of tissue
homogenate or cell lysate was separated on 4–12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gels and subjected to
immunoblotting using a primary antibody (1:100 dilution) and a
peroxidase-conjugated anti-rabbit or anti-mouse secondary antibody
(1:5000 dilution). The immunoreactive bands were detected using
ECL western blotting reagents (Thermo Fisher Scientific, Waltham,
MA). The intensity of immunoreactive bands was quantified by
densitometry (MultiGauge software, Fujifilm Holdings, Tokyo,
Japan). eNOS and phospho-eNOS, ERK and phospho-ERK, or Akt
and phospho-Akt were detected on the same gel following re-probing
of membranes. The signal intensities of the phosphorylated eNOS,
ERK, and Akt were normalized by the intensities of the total eNOS,
ERK, and Akt in each membrane, respectively.
Cell culture
HUVECs (1 105 cells/ml) were cultured in EGM-2 medium (Sanko
Junyaku, Tokyo, Japan) supplemented with 2% fetal bovine serum.
EGM-2 medium contains L-arginine of 5 104 mol/l. Passages 5–10
were used for the experiments. After the HUVECs were growth-
arrested in serum-free medium for 24 h, cells were incubated with
1 106 or 1 104 mol/l ADMA or the vehicle for 6 h. Ten minutes
after 10 ng/ml recombinant vascular endothelial growth factor (R&D
Systems, Minneapolis, MN) or the vehicle was applied to HUVECs, the
reaction was terminated by aspirating the medium. NO production was
estimated by measuring levels of NOx in the conditioned medium with
an assay kit (Dojindo Laboratories, Kumamoto, Japan).35 After three
washes with ice-cold phosphate-buffered saline on ice, cells were
homogenized in lysis buffer containing protease inhibitor cocktail.
Statistical analysis
Results are shown as mean±s.e.m. Area under the curve and IC50
values were calculated by GraphPad Prism (GraphPad, San Diego, CA)
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computer software using non-linear sigmoid curve fitting. Inter-
group differences were assessed by the Mann–Whitney U-test or
two-way analysis of variance followed by Tukey–Kramer’s post-hoc
analysis. A value of Po0.05 was considered statistically significant.
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